Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Aurinia Pharmaceuticals Inc's Business Segments
Aurinia Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
3
Largest Segment
Product
Total Revenue
$ 83
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Product0%
- Service9.6%
- License, Collaboration and Royalty Revenue9.6%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 153 | - |
| Service | $ 8 | 9.6% |
| License, Collaboration and Royalty Revenue | $ 8 | 9.6% |
Revenue by Product & Service Category - FY
- Product94.7%
- License, Collaboration and Royalty Revenue5.3%
- Service5.3%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 74 | 94.7% |
| License, Collaboration and Royalty Revenue | $ 4 | 5.3% |
| Service | $ 4 | 5.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Product0%
- Service9.6%
- License, Collaboration and Royalty Revenue9.6%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 153 | - |
| Service | $ 8 | 9.6% |
| License, Collaboration and Royalty Revenue | $ 8 | 9.6% |
Description of Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on the development of novel therapies for the treatment of lupus nephritis and other autoimmune diseases. The company is headquartered in Victoria, British Columbia, Canada, and was founded in 199
The company’s flagship drug candidate is voclosporin, which is a calcineurin inhibitor under development for the treatment of lupus nephritis. Lupus nephritis is a serious autoimmune disease that affects the kidneys and can lead to kidney failure. Currently, there are no FDA-approved treatments for lupus nephritis.
Aurinia is conducting a Phase 3 clinical trial of voclosporin in lupus nephritis, which is expected to be completed in 202 The company has also conducted Phase 2 trials of voclosporin in other autoimmune diseases, including dry eye syndrome and non-infectious uveitis.
In addition to voclosporin, Aurinia is developing a pipeline of other novel therapies for autoimmune diseases. The company’s pipeline includes drugs that target the complement system, a complex system of proteins that play a role in immune response and inflammation.
Aurinia has a strong intellectual property (IP) portfolio, including patents related to the composition of matter and the use of voclosporin and other compounds for the treatment of autoimmune diseases. The company has also formed strategic partnerships with other biopharmaceutical companies to develop and commercialize its drug candidates.
Aurinia has a talented and experienced management team, including CEO Peter Greenleaf, who has over 20 years of experience in the pharmaceutical industry. The company also has a strong financial position, with over $400 million in cash and investment securities as of December 31, 2020.
Overall, Aurinia Pharmaceuticals Inc. is a leading biopharmaceutical company focused on the development of novel therapies for the treatment of lupus nephritis and other autoimmune diseases. With a strong pipeline of drug candidates, a robust IP portfolio, and a talented management team, Aurinia is well-positioned to make a meaningful impact in the field of autoimmune diseases.
The company’s flagship drug candidate is voclosporin, which is a calcineurin inhibitor under development for the treatment of lupus nephritis. Lupus nephritis is a serious autoimmune disease that affects the kidneys and can lead to kidney failure. Currently, there are no FDA-approved treatments for lupus nephritis.
Aurinia is conducting a Phase 3 clinical trial of voclosporin in lupus nephritis, which is expected to be completed in 202 The company has also conducted Phase 2 trials of voclosporin in other autoimmune diseases, including dry eye syndrome and non-infectious uveitis.
In addition to voclosporin, Aurinia is developing a pipeline of other novel therapies for autoimmune diseases. The company’s pipeline includes drugs that target the complement system, a complex system of proteins that play a role in immune response and inflammation.
Aurinia has a strong intellectual property (IP) portfolio, including patents related to the composition of matter and the use of voclosporin and other compounds for the treatment of autoimmune diseases. The company has also formed strategic partnerships with other biopharmaceutical companies to develop and commercialize its drug candidates.
Aurinia has a talented and experienced management team, including CEO Peter Greenleaf, who has over 20 years of experience in the pharmaceutical industry. The company also has a strong financial position, with over $400 million in cash and investment securities as of December 31, 2020.
Overall, Aurinia Pharmaceuticals Inc. is a leading biopharmaceutical company focused on the development of novel therapies for the treatment of lupus nephritis and other autoimmune diseases. With a strong pipeline of drug candidates, a robust IP portfolio, and a talented management team, Aurinia is well-positioned to make a meaningful impact in the field of autoimmune diseases.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that specializes in developing and commercializing therapies for various autoimmune and inflammatory diseases. Its mission is strongly centered on advancing treatment options for patients with unmet medical needs, particularly in complex conditions that can be debilitating and life-altering.
Segments
Aurinia Pharmaceuticals Inc. operates within a singular segment focused on the research, development, and commercialization of pharmaceutical products. This segment encapsulates various activities including:
1. Research and Development (R&D): The company engages in extensive R&D to discover new therapies targeting autoimmune and inflammatory diseases. This process includes pre-clinical studies, clinical trials, and post-marketing studies to evaluate the safety and efficacy of their products.
2. Commercialization: Once products are developed and approved, Aurinia moves into the commercialization phase, which involves marketing, outreach to healthcare professionals, and building relationships with stakeholders in the healthcare community.
3. Patient Support Programs: Essential to Aurinias operations is their commitment to supporting patients diagnosed with the diseases they aim to treat. This includes initiatives related to medication adherence and disease management.
Products
The flagship product of Aurinia Pharmaceuticals is voclosporin, a novel calcineurin inhibitor specifically designed to target subsets of autoimmune conditions. Its primary therapeutic application includes:
- Lupus Nephritis: Voclosporin is approved for the treatment of lupus nephritis, a critical condition characterized by inflammation of the kidneys due to systemic lupus erythematosus (SLE), an autoimmune disease. Voclosporin works by modulating the immune response, thereby reducing inflammation and preventing further kidney damage. The unique mechanism of action allows it to be used alongside other standard treatments, providing comprehensive care for patients.
In addition to lupus nephritis, the company is engaged in ongoing research to evaluate the efficacy of voclosporin in other autoimmune diseases, including but not limited to:
- Focal Segmental Glomerulosclerosis (FSGS): A rare disease that can lead to nephrotic syndrome, characterized by proteinuria, low serum albumin levels, and edema. Research is being conducted to ascertain how voclosporin might benefit patients with this condition.
- Vasculitis: Aurinia also investigates voclosporins potential applications in treating this group of disorders that involve inflammation of blood vessels, which can further lead to complications affecting organs throughout the body.
Services
In conjunction with its pharmaceutical offerings, Aurinia Pharmaceuticals Inc. provides a range of support services centered around patient care and education:
1. Patient Education: Aurinia offers informational resources about lupus nephritis and other conditions, helping patients understand their disease and treatment options. This can include printed materials, online content, and interactive tools designed to facilitate better disease management.
2. Support Programs: The company has established patient support programs that aim to assist patients with medication management, including access to financial assistance, helping to navigate insurance issues, and connecting patients with healthcare professionals.
3. Healthcare Provider Collaboration: Aurinia also collaborates with healthcare professionals to improve treatment approaches through educational initiatives. This involves workshops, continuing medical education (CME) programs, and scientific collaborations to disseminate knowledge regarding the latest advancements in autoimmune disease management.
4. Clinical Trial Participation: The company encourages and facilitates participation in clinical trials, providing information and support to both patients and healthcare providers regarding ongoing studies that may benefit further research into autoimmune diseases.
In summary, Aurinia Pharmaceuticals Inc. is heavily invested in the field of immunology, focusing on innovative therapies that address serious medical needs. Through its segment in pharmaceutical development, its lead product voclosporin, and dedicated services aimed at improving patient outcomes, Aurinia aims to make a significant impact in the treatment landscape for autoimmune and inflammatory diseases.
Segments
Aurinia Pharmaceuticals Inc. operates within a singular segment focused on the research, development, and commercialization of pharmaceutical products. This segment encapsulates various activities including:
1. Research and Development (R&D): The company engages in extensive R&D to discover new therapies targeting autoimmune and inflammatory diseases. This process includes pre-clinical studies, clinical trials, and post-marketing studies to evaluate the safety and efficacy of their products.
2. Commercialization: Once products are developed and approved, Aurinia moves into the commercialization phase, which involves marketing, outreach to healthcare professionals, and building relationships with stakeholders in the healthcare community.
3. Patient Support Programs: Essential to Aurinias operations is their commitment to supporting patients diagnosed with the diseases they aim to treat. This includes initiatives related to medication adherence and disease management.
Products
The flagship product of Aurinia Pharmaceuticals is voclosporin, a novel calcineurin inhibitor specifically designed to target subsets of autoimmune conditions. Its primary therapeutic application includes:
- Lupus Nephritis: Voclosporin is approved for the treatment of lupus nephritis, a critical condition characterized by inflammation of the kidneys due to systemic lupus erythematosus (SLE), an autoimmune disease. Voclosporin works by modulating the immune response, thereby reducing inflammation and preventing further kidney damage. The unique mechanism of action allows it to be used alongside other standard treatments, providing comprehensive care for patients.
In addition to lupus nephritis, the company is engaged in ongoing research to evaluate the efficacy of voclosporin in other autoimmune diseases, including but not limited to:
- Focal Segmental Glomerulosclerosis (FSGS): A rare disease that can lead to nephrotic syndrome, characterized by proteinuria, low serum albumin levels, and edema. Research is being conducted to ascertain how voclosporin might benefit patients with this condition.
- Vasculitis: Aurinia also investigates voclosporins potential applications in treating this group of disorders that involve inflammation of blood vessels, which can further lead to complications affecting organs throughout the body.
Services
In conjunction with its pharmaceutical offerings, Aurinia Pharmaceuticals Inc. provides a range of support services centered around patient care and education:
1. Patient Education: Aurinia offers informational resources about lupus nephritis and other conditions, helping patients understand their disease and treatment options. This can include printed materials, online content, and interactive tools designed to facilitate better disease management.
2. Support Programs: The company has established patient support programs that aim to assist patients with medication management, including access to financial assistance, helping to navigate insurance issues, and connecting patients with healthcare professionals.
3. Healthcare Provider Collaboration: Aurinia also collaborates with healthcare professionals to improve treatment approaches through educational initiatives. This involves workshops, continuing medical education (CME) programs, and scientific collaborations to disseminate knowledge regarding the latest advancements in autoimmune disease management.
4. Clinical Trial Participation: The company encourages and facilitates participation in clinical trials, providing information and support to both patients and healthcare providers regarding ongoing studies that may benefit further research into autoimmune diseases.
In summary, Aurinia Pharmaceuticals Inc. is heavily invested in the field of immunology, focusing on innovative therapies that address serious medical needs. Through its segment in pharmaceutical development, its lead product voclosporin, and dedicated services aimed at improving patient outcomes, Aurinia aims to make a significant impact in the treatment landscape for autoimmune and inflammatory diseases.